Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus

Medicine (United States)

Volumn 96, Issue 27, 2017, Pages

  Li, Jian ^a   Gong, Yanping ^a   Li, Chunlin ^a   Lu, Yanhui ^a   Liu, Yu ^a   Shao, Yinghong ^b  

^a Department of Geriatric Endocrinology ^*  (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

meta analysis; metformin; SGLT2 inhibitor; sodium glucose cotransporter 2 inhibitor; type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; BRONCHITIS; CLINICAL EVALUATION; CONSTIPATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; GASTROENTERITIS; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INFLUENZA; KETOACIDOSIS; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; POLLAKISURIA; POLYURIA; POSITIONAL DIZZINESS; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; TIME FACTOR;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; MEMBRANE TRANSPORT MODULATORS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS;

EID: 85021996387     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007201     Document Type: Article

References (39)

1. WHO. Diabetes Factsheet 2016. Available at: Http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed on March 11, 2017.
2. Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther 2011;2:133-45.
3. Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum Indian J Endorinol Metab 2016;4:546-51.
4. Green J, FeinglosM. New combination treatments in the management of diabetes: Focus on sitagliptin-metformin. Vasc Health Risk Manage 2008;4:743-51.
5. Scheen AJ1, Paquot N. Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013;39:179-90.
6. American Diabetes AssociationApproaches to glycemic treatment. Diabetes Care 2015;38(Suppl):S41-8.
7. Garber AJ, AbrahamsonMJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438-47.
8. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacol Ther 2013;139:51-9.
9. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of Diabetes Mellitus: Cardiovascular and kidney effects, potential mechanisms, clinical applications. Circulation 2016;134:752-72.
10. Carlson CJ, Santamarina ML. Update review of the safety of sodiumglucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Saf 2016;15:1401-12.
11. Kipnes MS. Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: A review of Phase II and III trials. Clin Investig 2011;1:145-56.
12. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors: Systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375-93.
13. Plosker GL. Dapagliflozin: A review of its use in type 2 diabetes mellitus. Drugs 2012;72:2289-312.
14. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7.
15. Bailey CJ, Iqbal N, Tjoen C, et al. Dapagliflozin monotherapy in drugnaive patients with diabetes: A randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012;14:951-9.
16. Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: A phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2013; 15:432-40.
17. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial. Diabetes Care 2013;36:2508-15.
18. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013;36:3396-404.
19. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147-58.
20. Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses. Diabetes Res Clin Pract 2014;105:313-21.
21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary Control Clin Trials 1996;17:1-2.
22. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50.
23. Leiter LA, Shestakova MV, Trubitsyna NP, et al. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. Diabetes Res Clin Pract 2016;112:50-6.
24. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384-93.
25. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, metformin: An active-controlled, parallelgroup, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013;36:4015-21.
26. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia 2013;56:2582-92.
27. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
28. Nauck MA, Baranov O, Ritzel RA, et al. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation Diabetologia 2013;56:1878-83.
29. Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:691-700.
30. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013;11:43.
31. Fleming JW, Fleming LW, Davis CS. Fixed-dose combinations in type 2 diabetes-role of the canagliflozin metformin combination. Diabetes Metab Syndr Obes 2015;25:287-94.
32. Fala L. Invokamet (Canagliflozin plus Metformin HCl): First fixed-dose combination with an sglt2 inhibitor approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits 2015;8:70-4.
33. Jabbour SA, Whaley JM, Tirmenstein M, et al. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med 2012;124:62-73.
34. US Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at: Http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed May 9, 2016.
35. Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose cotransporter 2 inhibitor. Postgrad Med 2014;126:7-17.
36. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-71.
37. Doggrell SA, McIntyre K.Canagliflozin-something newfor type 2 diabetes, but is it safe and efficacious Expert Opin Pharmacother 2014;15:437-41.
38. Davis SN. Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial). Expert Rev Clin Pharmacol 2014;7:21-3.
39. Bailey T. Options for combination therapy in type 2 diabetes: Comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med 2013;126:S10-20.